Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase von Bruchas, Michael R., Yang, Tao, Schreiber, Selena, DeFino, Mia, Kwan, Steven C., Li, Shuang, Chavkin, Charles

Volltext

The absence of endogenous β-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation von Petraschka, M, Li, S, Gilbert, T.L, Westenbroek, R.E, Bruchas, M.R, Schreiber, S, Lowe, J, Low, M.J, Pintar, J.E, Chavkin, C

Volltext

Long-Acting κ Opioid Antagonists Disrupt Receptor Signaling And Produce Noncompetitive Effects By Activating C-Jun N-Terminal Kinase von Michael R. Bruchas, Tao Yang, Selena Schreiber, Mia DeFino, Steven C. Kwan, Shuang Li, Charles Chavkin

Volltext

First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors von LoRusso, Patricia M., Goncalves, Priscila H., Casetta, Lindsay, Carter, Judith A., Litwiler, Kevin, Roseberry, Dale, Rush, Selena, Schreiber, Jennifer, Simmons, Heidi M., Ptaszynski, Mieke, Sausville, Edward A.

Volltext

Abstract 2028: PDE3A modulation for cancer therapy von Wu, Xiaoyun, Lewis, Timothy, Waal, Luc de, Gao, Galen, Zhang, Jian, Schenone, Monica, Garvie, Colin, Diamond, Brett, Lorrey, Selena, Cherniack, Andrew, Corsello, Steven, Burgin, Alex, Golub, Todd, Schreiber, Stuart, Meyerson, Matthew, Greulich, Heidi

Volltext

Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM) von Zonder, Jeffrey A, Usmani, Saad, Scott, Emma C., Hofmeister, Craig C., Lendvai, Nikoletta, Berdeja, Jesus G., Anderson, Larry D., Hari, Parameswaran, Singhal, Seema, Orloff, Gregory, Craig, Michael, Valent, Jason, Lee, Wes, Hart, Lowell, Hrom, J, Tarantolo, Stephano, Faber, Edward, Schiller, Gary J, Schreiber, Jennifer, Oliver, Colleen, Rush, Selena A, Tunquist, Brian, Ptaszynski, Mieke, Raje, Noopur S.

Volltext

Abstract A252: A phase 1 study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF1R), in patients with advanced or metastatic cancers von Bendell, Johanna C., Tolcher, Anthony W., Jones, Suzanne F., Beeram, Muralidhar, Infante, Jeffrey R., Larsen, Paul, Rasor, Kevin, Garrus, Jennifer E., Li, Jinfang, Cable, P. Louann, Eberhardt, Christine, Schreiber, Jennifer, Rush, Selena, Wood, Kenneth W., Barrett, Emma, Patnaik, Amita

Volltext